SG11201607137WA - Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain - Google Patents
Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gainInfo
- Publication number
- SG11201607137WA SG11201607137WA SG11201607137WA SG11201607137WA SG11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA SG 11201607137W A SG11201607137W A SG 11201607137WA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- weight gain
- Prior art date
Links
- 229940124604 anti-psychotic medication Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000004584 weight gain Effects 0.000 title 1
- 235000019786 weight gain Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946003P | 2014-02-28 | 2014-02-28 | |
| US201462056250P | 2014-09-26 | 2014-09-26 | |
| US201462059358P | 2014-10-03 | 2014-10-03 | |
| PCT/CA2015/050145 WO2015127557A1 (en) | 2014-02-28 | 2015-02-27 | Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607137WA true SG11201607137WA (en) | 2016-09-29 |
Family
ID=54008095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607137WA SG11201607137WA (en) | 2014-02-28 | 2015-02-27 | Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10662475B2 (en) |
| EP (1) | EP3111352A4 (en) |
| JP (1) | JP6588919B2 (en) |
| KR (1) | KR20160138071A (en) |
| CN (1) | CN106462668A (en) |
| AU (1) | AU2015222658B2 (en) |
| CA (1) | CA2940908C (en) |
| IL (1) | IL247410B (en) |
| SG (1) | SG11201607137WA (en) |
| WO (1) | WO2015127557A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| US20190046532A1 (en) * | 2015-09-30 | 2019-02-14 | Indivior Uk Limited | Psychiatric treatment for patients with gene polymorphisms |
| CN105467028A (en) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | A method of separating and measuring optical isomers of a lurasidone intermediate by gas chromatography |
| AU2017218149B2 (en) | 2016-02-12 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Methods and systems for detection of abnormal karyotypes |
| US11337932B2 (en) | 2016-12-20 | 2022-05-24 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN110087640A (en) | 2016-12-20 | 2019-08-02 | 罗曼治疗系统股份公司 | Transdermal therapeutic system comprising asenapine |
| JP2020525545A (en) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112704672A (en) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | Transdermal therapeutic system comprising asenapine |
| CN109207582A (en) * | 2018-10-22 | 2019-01-15 | 南通中科基因医学检验所有限公司 | Clozapine Personalized Medicine Genetic Testing Kit |
| CN118841129B (en) * | 2024-09-23 | 2024-12-13 | 深圳人体密码基因科技有限公司 | Gene detection report generation method and system based on medication risk assessment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| PT728218E (en) | 1993-11-12 | 2008-04-08 | Phri Properties Inc | Hybridization probes for nucleic acid detection, universal stems, methods and kits |
| AU2002363329A1 (en) * | 2001-11-06 | 2003-05-19 | Elizabeth Gray | Pharmacogenomics-based system for clinical applications |
| US20060177847A1 (en) * | 2004-12-09 | 2006-08-10 | Perlegen Sciences, Inc. | Markers for metabolic syndrome obesity and insulin resistance |
-
2015
- 2015-02-27 CN CN201580022846.8A patent/CN106462668A/en active Pending
- 2015-02-27 KR KR1020167026775A patent/KR20160138071A/en not_active Withdrawn
- 2015-02-27 SG SG11201607137WA patent/SG11201607137WA/en unknown
- 2015-02-27 JP JP2016554462A patent/JP6588919B2/en not_active Expired - Fee Related
- 2015-02-27 AU AU2015222658A patent/AU2015222658B2/en not_active Ceased
- 2015-02-27 WO PCT/CA2015/050145 patent/WO2015127557A1/en not_active Ceased
- 2015-02-27 US US15/122,101 patent/US10662475B2/en active Active
- 2015-02-27 CA CA2940908A patent/CA2940908C/en active Active
- 2015-02-27 EP EP15754639.1A patent/EP3111352A4/en not_active Withdrawn
-
2016
- 2016-08-22 IL IL247410A patent/IL247410B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015222658A1 (en) | 2016-09-08 |
| US20170073755A1 (en) | 2017-03-16 |
| EP3111352A4 (en) | 2017-08-30 |
| KR20160138071A (en) | 2016-12-02 |
| JP2017506518A (en) | 2017-03-09 |
| EP3111352A1 (en) | 2017-01-04 |
| WO2015127557A1 (en) | 2015-09-03 |
| US10662475B2 (en) | 2020-05-26 |
| JP6588919B2 (en) | 2019-10-09 |
| CN106462668A (en) | 2017-02-22 |
| CA2940908A1 (en) | 2015-09-03 |
| IL247410A0 (en) | 2016-11-30 |
| IL247410B (en) | 2020-05-31 |
| AU2015222658B2 (en) | 2021-07-08 |
| CA2940908C (en) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| ZA201705908B (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
| IL247410A0 (en) | Compositions and methods for the treatment and prevention of antipsychotic medication-induced weight gain | |
| IL247515A0 (en) | Cenicriviroc for the treatment of fibrosis | |
| ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
| HUE056172T2 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
| PL3102555T3 (en) | Compositions of compounds and uses thereof | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
| IL246721B (en) | Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| EP3113788A4 (en) | Methods and compositions for the protection of sensory cells | |
| PT3122349T (en) | Compositions for the treatment of autodigestion | |
| IL253220A0 (en) | Compositions and methods for treating glaucoma | |
| PL3113774T3 (en) | Compositions of grapiprant and methods for using the same | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| IL248846A0 (en) | Methods and compositions of dasotraline for treatment of adhd | |
| EP3104940A4 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis | |
| AU2014904752A0 (en) | Methods for the treatment and prevention of iron overload | |
| GB201418272D0 (en) | Composition & methods of treatment | |
| GB201418268D0 (en) | Composition & methods of treatment | |
| HK1231001A1 (en) | Compositions and methods for the prevention and/or treatment of schistosomiasis |